Biovitrum Appoints The Bank of New York Mellon as Depositary Bank

* Reuters is not responsible for the content in this press release.

Tue Jul 7, 2009 9:07am EDT 

  STOCKHOLM, SWEDEN, Jul 07 (MARKET WIRE) -- 

STOCKHOLM - July 7, 2009 - Biovitrum AB (publ) (STO: BVT) has selected
The Bank of New York Mellon (NYSE: BK), as the depositary bank for its
Level I American depositary receipt (ADR) program. Each Biovitrum ADR
represents one common share and trades on the over-the-counter market.
The common shares trade on the Stockholm OMX Nordic Exchange under the
symbol "BVT."

    "We are very happy with the agreement with The Bank of New York Mellon as
it has a strong and proven track record," said Martin Nicklasson, CEO of
Biovitrum. "We wish to optimize U.S. investor access to our share, and we
believe the Bank has the resources and expertise necessary to help us
achieve that goal."

    "We look forward to helping Biovitrum unlock the potential of the U.S.
capital markets," said Michael Cole-Fontayn, chief executive officer of
The Bank of New York Mellon's Depositary Receipt Division. "As the
world's leading depositary, The Bank of New York Mellon will utilize its
resources to develop a long and mutually beneficial partnership with
Biovitrum and its investors."

    About Biovitrum Biovitrum is an international pharmaceutical company that
markets specialist pharmaceuticals in several regions. Using its expertise
and experience Biovitrum takes scientific innovation to patients with
significant unmet medical need. Research expertise and capabilities are
focused on development and production of biotechnology therapeutics
within our prioritized areas of hemophilia, inflammation/autoimmune
diseases, cancer supportive care and malabsorption. The company has
revenues of approximately SEK 1.2 billion and around 400 employees. The
company head office is located in Sweden and it is listed on the
Stockholm OMX Nordic Exchange. For more information please visit
www.biovitrum.com

    About Bank of New York Mellon The Bank of New York Mellon acts as
depositary for more than 2,100 American and global depositary receipt
programs, acting in partnership with leading companies from 67 countries.
With an unrivalled commitment to helping securities issuers succeed in the
world's rapidly evolving financial markets, the Company delivers the
industry's most comprehensive suite of integrated depositary receipt,
corporate trust and stock transfer services. Additional information is
available at www.bnymellon.com/dr.

    Biovitrum AB (publ) may be required to disclose the information provided
herein pursuant to the Swedish Securities Markets Act. The information
was provided for public release on July 7, 2009 at 3.00 p.m. CET.

    This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.

    Copyright Copyright Hugin AS 2009. All rights reserved.

    

For more information please contact:

Biovitrum
Martin Nicklasson, CEO
Phone: +46 8 697 2545

Goeran Arvidson, CFO
Cell phone: +46 70 633 30 42

Erik Kinnman, VP Investor Relations
Cell phone: +46 73 422 15 40
Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.